Biotech Valuations Rise as New Clinical Platforms Show Progress
BioMedWire Editorial Coverage: As advanced biotech programs move closer to commercialization, fair-value adjustments under U.S. Generally Accepted Accounting Principles (“GAAP”) are increasingly recognized as meaningful signals of real scientific and business advancement. These valuations help translate research achievements into quantifiable economic impact, giving investors clearer insight into how innovation converts into company value. Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile) this trend as it prepares for a major fair-value update on its 45% ownership in joint venture (“JV”) partner GMP Bio, following a new independent assessment that points to a substantial increase in the asset’s worth. This development further reinforces Oncotelic…











